Zaid M R, Hasan M, Khan A A
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka.
J Diarrhoeal Dis Res. 1995 Mar;13(1):44-6.
A double-blind placebo-controlled study was carried out to assess the therapeutic effects of Attapulgite, a purified hydrated aluminium magnesium silicate, as an additional agent to oral rehydration solutions in 30 adults with mild-to-moderate acute diarrhoea where no bacterial or protozoal causes could be identified. The study subjects were give 600 mg tablets of Attapulgite or placebo in a random order and followed up for 72 hours. Attapulgite was observed to be significantly better than placebo in reducing the severity and duration of diarrhoea in terms of frequency of motion and consistency of stools (p < 0.01), severity of dehydration (p < 0.01) and in reducing the amount of ORS consumed (p < 0.05). Attapulgite was also well-tolerated. Attapulgite, therefore, merits attention as an additional safe agent besides ORS for the treatment of mild-to-moderate acute diarrhoea.
开展了一项双盲安慰剂对照研究，以评估凹凸棒石（一种纯化的水合铝硅酸镁）作为口服补液溶液的辅助药物，对30名患有轻度至中度急性腹泻且未查明细菌或原生动物病因的成年人的治疗效果。研究对象被随机给予600毫克凹凸棒石片剂或安慰剂，并随访72小时。在减少腹泻的严重程度和持续时间方面，从排便频率和粪便稠度来看，凹凸棒石明显优于安慰剂（p < 0.01）；在脱水严重程度方面（p < 0.01），以及在减少口服补液溶液的消耗量方面（p < 0.05），凹凸棒石也明显优于安慰剂。凹凸棒石的耐受性也良好。因此，凹凸棒石作为除口服补液溶液之外用于治疗轻度至中度急性腹泻的一种额外的安全药物，值得关注。
